Clinical Trial Update: Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift [Phase 2]

View source ↗

Summary

Phase 2 trial assessing SPI-1005 for otoprotection to prevent temporary auditory threshold shifts has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Temporary Auditory Threshold Shift

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Temporary Auditory Threshold Shift | Phase 2 | Status: COMPLETED